Navigation Links
Epeius Biotechnologies to Partner at BIO Investor Forum
Date:10/20/2009

SAN FRANCISCO, Oct. 20 /PRNewswire/ -- Epeius Biotechnologies Corporation, an emerging leader in the field of targeted genetic medicine, announced today that Frederick L. Hall, President and CEO, and Dr. Erlinda M. Gordon, Medical Director, will be participating in the 8th Annual BIO Investor Forum being held October 28-29, 2009, at the Palace Hotel in San Francisco. Participating companies that are poised for leadership status in areas of therapeutic innovation are chosen through a competitive screening process, with input by an advisory committee comprised of members from top-tier firms focused on investing and banking in the life sciences industry.

The selection of Epeius Biotechnologies as an investment opportunity was based on the accomplishment of significant clinical development milestones with its lead oncology product, Rexin-G, a tumor-targeted anti-cancer agent that is approved for use against all solid tumors by the Philippine FDA, and has recently received both Orphan Drug priorities and Fast Track designation by the U.S. FDA.

Epeius Biotechnologies is among a select group of companies which are recognized as those that are creating real value through development-stage programs with near-term clinical catalysts. According to the top-tier investor forum advisory committee, "These are the companies that will help drive the investment and deal making in the life sciences sector and global innovation in healthcare."

This prestigious forum provides an opportunity for senior management of Epeius Biotechnologies to showcase the remarkable clinical development of Rexin-G®, as stand-alone therapy for otherwise intractable metastatic cancers, and to partner with savvy investors that are capable of expediting the development of Rexin-G in the larger global market.

About Epeius Biotechnologies

Epeius Biotechnologies Corporation is a privately held biopharmaceutical company dedicated to the advancement of genetic medicine with the development and commercialization of its leading oncology products and its tumor-targeted delivery systems.

To learn more about our pipeline of proprietary biotechnologies currently available for clinical development and/or new product development, please visit us at http://www.epeiusbiotech.com .

*(LOGO 300dpi: www.Send2Press.com/mediaboom/09-1012-EpeiusBio_300dpi.jpg)

This release was issued on behalf of the above organization by Send2Press(R), a unit of Neotrope(R). http://www.Send2Press.com

SOURCE Epeius Biotechnologies


'/>"/>
SOURCE Epeius Biotechnologies
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Beginners Luck, or Creative Artists of the First Rank? Epeius Biotechnologies Launches Rexin-G eBook Tutorial
2. Epeius Biotech Awarded Patents in Europe for Targeted Genetic Anti-Cancer Medicine: Company Expands Impressive Intellectual Property Estate
3. Targeting Metastatic Cancer From the Inside: Epeius Biotech Reveals a New Generation of Tools for Medical Gene Delivery
4. Epeius Biotechnologies Lead Product, Rexin-G for Metastatic Cancer, Aptly Highlighted by National Cancer Institute Journal
5. FDA Grants Epeius Biotechnologies Rexin-G a Third Orphan Drug Designation, This Time for the Treatment of Soft Tissue Sarcomas
6. Epeius Biotechnologies Tumor-Targeted Rexin-G Receives FDA Orphan Drug Designation for the Treatment of Osteosarcoma
7. Epeius Biotechnologies Awarded U.S. Patent for Targeted Injectable Gene Delivery In Vivo
8. Epeius Biotechnologies Leads With Keynote Address on the Advent of Pathotropic Medicine for Cancer at the Global Pharma R&D Summit Conference in Boston MA
9. Variation Biotechnologies Names Jeff Baxter CEO
10. TriLink BioTechnologies, Inc. Relaunches Oligonucleotide Radiolabeling Services
11. TriLink BioTechnologies to Sponsor GIVING HUNGER THE BLUES, a Benefit Concert to Help Alleviate Hunger in San Diego County
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)...  VMS BioMarketing, a leading provider of patient support solutions, ... Educator (CNE) network, which will launch this week. The VMS ... care professionals to enhance the patient care experience by delivering ... health care professionals to help women who have been diagnosed ... ...
(Date:10/11/2017)... ... ... Disappearing forests and increased emissions are the main causes of the evolving air ... living in larger cities are affected by air pollution related diseases. , That is ... globally - decided to take action. , “I knew I had to take action ...
(Date:10/11/2017)... Florida (PRWEB) , ... October 11, 2017 , ... ... Drug Administration (FDA) has granted orphan drug designation to SBT-100, its novel anti-STAT3 ... for the treatment of osteosarcoma. SBT-100 is able to cross the cell membrane ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... company advancing targeted antibody-drug conjugate (ADC) therapeutics, today confirmed licensing rights that ... Polymerized Liposomal Nanoparticle), a technology developed in collaboration with Children’s Hospital Los ...
Breaking Biology Technology:
(Date:6/23/2017)... ARMONK, N.Y. and ITHACA, N.Y. ... IBM ) and Cornell University, a leader in dairy ... combined with bioinformatics designed to help reduce the chances ... breaches. With the onset of this dairy project, Cornell ... the Consortium for Sequencing the Food Supply Chain, a ...
(Date:5/6/2017)... -- RAM Group , Singaporean based technology ... biometric authentication based on a novel  quantum-state ... perform biometric authentication. These new sensors are based on a ... Group and its partners. This sensor will have widespread ... security. Ram Group is a next generation sensor ...
(Date:4/13/2017)... April 13, 2017 UBM,s Advanced Design and ... will feature emerging and evolving technology through its 3D ... will run alongside the expo portion of the event ... and demonstrations focused on trending topics within 3D printing ... and manufacturing event will take place June 13-15, 2017 at ...
Breaking Biology News(10 mins):